Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CMOP in newly diagnosed DLBCL
NCT05777369Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators
01
Overview
Open-label, single-arm trial of mitoxantrone in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Status: unknown.
02
Drugs
mitoxantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05777369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777369.